My Journey

Over the past few months, I’ve been closely tracking Aarti Drugs Ltd, a key player in India’s pharmaceutical and specialty chemicals space. This wasn’t just another trade — it was a conviction-driven decision backed by strong fundamentals, technical indicators, and management commentary. ▶ Why I Entered Aarti Drugs Fundamental Value with Upcoming Growth Triggers:Aarti Drugs has undergone a phase of strategic expansion in APIs, formulations, and specialty chemicals. The management's FY26 revenue guidance of ₹3,000 Cr, coupled with expected EBITDA margins of 15–16%, signals a margin-accretive growth trajectory. USFDA Approval & Global Expansion:The lifting of the import alert on the Tarapur facility in Feb 2025 is a major development. It not only unlocks exports to the US again but is also expected to improve visibility in the European market. This paves the way for better pricing, higher volumes, and wider reach. New Product Pipeline:APIs like Metformin, Salicylic Acid,...

On April 6, 2024, I published a blog titled "Will Dreamfolks Services Become a Multibagger?" , where I expressed optimism about Dreamfolks Services Ltd., a leading airport service aggregator in India. At the time, the travel sector was riding a wave of post-pandemic recovery, and Dreamfolks’ asset-light, technology-driven business model appeared poised for growth. The company’s dominance in the airport lounge access market, with an estimated 95% market share for card-based domestic lounge access in 2022, coupled with its diversification into services like golf, spa, and beauty offerings, fueled my bullish outlook. I initiated a position in Dreamfolks Services at prices ranging between ₹450 and ₹500 from October 2023 to August 2024, confident in its potential to capitalize on rising travel demand and its innovative service expansions. During this period, I sold half my position at approximately ₹525, locking in a healthy profit. However, on February 10, 2025, I made the deci...